Background {#Sec1}
==========

Staphylococcal infections still remain an important cause of mortality and morbidity worldwide despite the development of antimicrobial agents. Among the staphylococcus species, *Staphylococcus aureus* is the most virulent species of the genus causing both nosocomial and community acquired infections worldwide \[[@CR1]\]. The organism has been found to be the most common bacterial agent recovered from blood stream infections, skin and soft tissue infections, pneumonia and hospital acquired post operative wound infections \[[@CR2]\]. Changes in the drug susceptibility profile of *S. aureus* have been reported worldwide; thereby making treating infections caused by *S. aureus* more difficult \[[@CR3]--[@CR5]\].

Dramatic changes in the susceptibility of *S. aureus* to beta-lactam antibiotics particularly to penicillin and cephalosporin in both hospital and community settings have been reported worldwide \[[@CR6]\]. Several mechanisms for the development of MRSA have been reported. Among these production of a unique penicillin-binding protein (PBP) that has a low affinity for β-lactam antibiotics and whose effects are determined by several structural genes (e.g., mecR1 and mecI) \[[@CR7], [@CR8]\], production of the usual PBPs, but with modified affinities for β-lactam drugs, and production of penicillinase enzyme are most important ones \[[@CR9]\].

MRSA spreads more readily than other strains once introduced into hospitals, and are often difficult to eradicate once established. In some countries MRSA make up to 75 % of all *S. aureus* isolates in hospitals \[[@CR10]\]. Transmission of MRSA occurs primarily from colonized or infected patients or staff to other patients or staff, or vice versa \[[@CR11]\]. Prevalence, however, varies markedly in hospitals in the same country and from one country to another. Furthermore, in Ethiopia, little information exists regarding prevalence and drug susceptibility pattern of methicillin resistant *S. aureus* isolated from various clinical samples. Therefore, studies on the prevalence and drug susceptibility patterns of *S. aureus* are of the highest priorities.

Methods {#Sec2}
=======

Study setting and context {#Sec3}
-------------------------

A cross sectional study was conducted among 1360 study participants at Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia from September 2013 to April 2014. The hospital is a tertiary level referral and teaching hospital which provides health care services to patients in and around Addis Ababa, the capital city of the country.

Specimen collection and processing {#Sec4}
----------------------------------

Clinical samples were collected from participants by employing standard microbiological procedures. Nasal swab, pus from wound, ear discharge, blood, throat swab, eye swab, vaginal discharge, urethral discharge, urine, stool, sputum, CSF and body fluids were clinical specimens collected. All specimens were transported to microbiology laboratory of the hospital with minimum delay for culture and sensitivity tests.

Clinical specimens were inoculated onto blood agar base (Oxoid, Basingstoke, Hampshire, England) to which 5 % sheep blood was added and mannitol salt agar (Oxoid, Basingstoke, Hampshire, England) by using streaking method. Inoculated plates were incubated at 35--37 °C for 18 to 24 h aerobically. Bacterial colonies showing typical characteristics of *S. aureus* (i.e., beta hemolytic on blood agar and colonies with golden yellow pigmentation on mannitol salt agar) were subjected to subculture on to basic media, gram stain and biochemical tests catalase and coagulase. Catalase positive and gram positive bacteria appearing in grape like cluster was spot inoculated to DNase agar (Oxoid, Basingstoke, Hampshire, England). Inoculated DNAse agar plates were incubated at 37 °C over night and flooded with 1 N HCl (Merk, Darmstadt, Germany). Isolates that hydrolyzed DNA in DNAse agar were considered *S. aureus*.

Antimicrobial susceptibility testing {#Sec5}
------------------------------------

Antimicrobial susceptibility test was carried out by Kirby Bauer disc diffusion method as per Clinical Laboratory Standards Institute (CLSI, 2013) guidelines on Muller Hinton agar (Oxoid, Basingstoke, England) for 11 antimicrobials \[[@CR12]\]. The growth suspension was prepared in 0.5 ml of the same broth medium and the turbidity was adjusted to match that of 0.5 McFarland standards to obtain approximately the organism number of 1 × 10^6^ colony forming units (CFU) per ml. A sterile swab was dipped into the suspension and the excess of inoculum was removed by pressing it against the sides of the tube. Then the swab was applied to the center of Muller Hinton agar plat and evenly spread on the medium. Antibiotic discs were placed after 15 min of inoculation to Muller Hinton agar seeded with each isolate and were incubated for 24 h at 35--37 °C. The diameter of the zone of inhibition around the disc was measured using sliding metal caliper.

Vancomycin susceptibility test was done by agar dilution and E test (Epsilometer) techniques. Agar dilution test involves the incorporation of varying concentrations of vancomycin into an agar medium, using serial twofold dilutions, followed by the application of a defined *S. aureus* inoculum to the agar surface of the plate. These results are interpreted based on determination of MIC of vancomycin in μg/ml (usually 2 μg/ml to16μg/ml concentration) for *S. aureus*. E test is manufactured by biomerieux, consists of a predefined, continuous and exponential gradient of antibiotic concentrations immobilized along a rectangular plastic test strip. After 48 h incubation a drop-shaped inhibition zone intersects the graded test strip at the inhibitory concentration of the antibiotic. Vancomycin resistant strains were also checked in reference laboratory at EPHI by Broth Microdilution (BMD) method before declaring as resistant. In this broth microdilution, susceptibility panel in 96-well microtiter plates were containing various concentration of antimicrobial agents. Then, standardized numbers of bacteria was inoculated into the wells of 96-well microtiter and incubate overnight at 35 °C. The MIC value was observed as the lowest concentration where no viability was observed in the wells of 96-microwell plates after incubation \[[@CR13]\].

Beta-lactamase production test {#Sec6}
------------------------------

All *S. aureus* strains were screened for beta-lactamase production by employing nitocefin, the procedures of Efuntoye et al. \[[@CR14]\]. Culture of each isolates was streaked onto sticks impregnated with nitocefin a chromogenic cephalosporin (Unipath Limited, Hampshire, England) that produces a rapid color change from yellow to pink/red when the beta-lactam ring is hydrolyzed by beta-lactamase.

Ethical approval {#Sec7}
----------------

The study was conducted after it was ethically reviewed and approved by the Department of Research and Ethical Review Committee of Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University. Ethical clearance was also obtained from Addis Ababa Health Bureau. Then permission was obtained from Yekatit 12 Hospital Medical College. Informed written consent was obtained from participants before data collection. All the information obtained from the study subjects were coded to maintain confidentially. When the participants were found to be positive for *S. aureus,* they were informed by the hospital clinician and received proper treatment.

Definition of terms {#Sec8}
-------------------

MRSA is defined as zone of inhibition less than or equal to 21 mm on MHA with 30 μg cefoxitin disc seeded with growth suspension of *S. aureus* isolates adjusted to 0.5 McFarland standards \[[@CR12]\].

MDR is defined as non-susceptibility to at least one agent in three or more antimicrobial categories \[[@CR13]\]. MIC is the lowest concentration of the antimicrobial agent that inhibits visible growth of the organism after a 24-hour incubation period.

Statistical analysis and quality assurance {#Sec9}
------------------------------------------

The reliability of the study findings were guaranteed by implementing quality control measures throughout the whole processes of laboratory work. *S. aureus* ATCC 25923 is a methicillin susceptible strain was used to check the conditions were favorable for detection of resistance. This strain was obtained from Ethiopian Public Health Institute (EPHI). Data were coded, entered and analyzed using SPSS software version 20 (SPSS INC, Chicago, IL, USA). Binary logistic regression was used to determine the association between *S. aureus* and clinical specimens. Multivariate logistic regressions were used to control confounding factors. *P*-values less than 0.05 were taken as statistically significant.

Results {#Sec10}
=======

Socio-demographic characteristics of participants {#Sec11}
-------------------------------------------------

A total of 1360 study participants were enrolled in the present study of which (654, 48.1 %) were males and (706, 51.9 %) females with a sex ratio of 0.93:1. The ages of study subjects ranged from 1 month to 89 years with a mean age of 23.4 ± 0.5 years and median age of 21 ± 0.5 years. Most of study participants were in the age group of 1--14 years (461, 33.9 %).

Prevalence of *S. aureus* {#Sec12}
-------------------------

Of a total of 1360 clinical samples *S. aureus* was isolated from (194, 14.3 %). Males had a higher isolation rate of *S. aureus* than females (106, 16.2 %) versus (88, 12.5 %). Rate of isolation of *S. aureus* was the highest in 15--24 years (46, 21.0 %). The isolation rate of *S. aureus* was not significantly associated with sex \[AOR, 95 % CI: 1.05(0.72, 1.53), *p* = 0.771\] and age groups (*p* \>0.05) (Table [1](#Tab1){ref-type="table"}).Table 1Association of *S. aureus* in study participants with regard to gender and age group at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, EthiopiaVariablePresence of *S. aureus*COR(95 % CI)*P*-valueAOR(95 % CI)*P*-valueYes (N/%)No (N/%)SexMale106(16.2)548(83.8)0.73(0.54, 0.99)0.0491.05(0.72,1.53)0.771Female88(12.5)618(87.5)1-1-Age group\<19(8.6)96(91.4)1.47(0.55, 3.92)0.434\--1--1448(10.4)413(89.6)1.19(0.55, 2.54)0.651\--15--2446(21.0)164(79.0)0.49(0.23, 1.06)0.072\--25--3438(17.0)184(83.0)0.67(0.31, 1.46)0.315\--35--4426(16.8)129(83.2)0.68(0.30, 1.55)0.366\--45--6418(13.6)115(86.4)0.88(0.37, 2.08)0.779\--\> = 659(12.2)65(87.8)1\-\--*COR* crude odds ratio, *AOR* adjusted odds ratio, *CI* Confidence interval

Isolation rate of *S. aureus* from clinical samples {#Sec13}
---------------------------------------------------

In current study the major sources of *S. aureus* were pus/abscess, ear discharge, blood, nasal swab and throat swab which together, accounted for (175, 90.2 %) of all isolates. The rest of the isolates were from urine, vaginal discharge, eye swab, body fluid, stool and sputum, accounting less than 10.0 % of the total. No *S. aureus* was isolated from CSF (0/97) and urethral discharge (0/19). The recovery rate of *S. aureus* was significantly associated with pus \[AOR, 95 % CI: 67.07(9.1, 493.8), *p* = 0.001\], nasal swab \[AOR, 95 % CI: 27(3.19, 228.05), *p* = 0.002\], throat swab \[AOR, 95 % CI: 11.1(1.3, 94.37), *p* = 0.027\] and ear discharge \[AOR, 95 % CI: 21.2(2.8, 162.3), *p* = 0.003\] (Table [2](#Tab2){ref-type="table"}).Table 2Isolation rate of *S. aureus* from clinical specimens at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, EthiopiaSpecimen typePresence of *S. aureus*TotalAOR95 % CI*P*-valueYes (N/%)No (N/ %)N^a^Pus/abscess118(55.4)95(44.6)21367.074(9.11, 493.8)0.001^\*\*^Nasal swab9(33.3)18(66.7)2727.000(3.19, 228.05)0.002^\*\*^Throat swab7(17.0)34(83.0)4111.118(1.31, 94.37)0.027^\*^Vaginal discharge3(2.5)118(97.5)1211.373(0.14, 13.50)0.786Urine6(2.8)211(97.2)2171.536(0.18, 13.02)0.694Eye swab2(12.5)14(87.5)167.714(0.65, 91.32)0.105Blood17(7.6)206(92.4)2234.456(0.58, 34.23)0.151Body fluids4(5.3)71(94.7)753.042(0.33, 28.0)0.326Stool3(1.8)168(98.2)1710.964(0.09, 9.46)0.975Ear discharge24(28.2)61(71.8)8521.246(2.78, 162.3)0.003^\*\*^Sputum1(0.8)54 (98.2)551\--*AOR* adjusted odds ratio^a^ Total sample^\*\*^ Significant at *P* value \< 0.01, ^\*^ Significant at *P* value \< 0.05

Prevalence of MRSA {#Sec14}
------------------

Out of 194 *S. aurues* recovered, (34, 17.5 %) were found out to be MRSA and the remaining (160, 82.5 %) were MSSA (Fig. [1](#Fig1){ref-type="fig"}). Relatively a higher number of MRSA were isolated in males (19, 19.9 %) than in females (15, 17.0 %) and the highest number of MRSA were detected in the age group 35--44 years (8, 30.8 %), followed by age group 45--64 years (5, 27.8 %), above 64 years (2, 22.2 %), 15--24 years (7, 17.4 %), 1--14 years (7, 14.6 %), and 25--34 years (4, 10.5 %). The isolation rate of MRSA in relation to gender was not significantly associated \[COR, 95 % CI: 0.94(0.44, 1.98), *p* = 0.87\] as well as any of age groups (*p* \>0.05) (Table [3](#Tab3){ref-type="table"}).Fig. 1Methicillin susceptibility pattern of *S. aureus* from participants at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, EthiopiaTable 3Association of methicillin resistant pattern of *S. aureus* in study participants with gender and age group at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, EthiopiaVariableMRSAMSSA*S. aureus*COR95 % CI*P*-valueN (%)N (%)NSexMale19(19.9)87(82.1)1060.94(0.44, 1.98)0.873Female15(17.0)73(83.0)881\--Age group\<10(0)9(100)90.00-0.9991--147(14.6)41(85.4)481.67(0.29, 9.76)0.56715--248(17.4)38(82.6)461.36(0.24, 7.78)0.73225--344(10.5)34(89.5)382.43(0.37, 15.95)0.35635--448(30.8)18(69.2)260.64(0.11, 3.80)0.62645--645(27.8)13(72.2)180.74(0.11, 4.86)0.757\> = 652(22.2)7(77.8)91\--*COR* crude odds ratio

The major source of MRSA was pus (24/118), nasal swab (3/9), ear discharge (3/24), throat swab (2/7) and blood (2/17). No MRSA was observed in urine, stool, body fluid, eye swab, sputum and vaginal discharge. Blood (15, 88.2 %) had higher percentage of MSSA followed by ear discharge (21, 87.5 %) and pus (94, 79.7 %). There was no statistical association between isolation rates of MSRA with any of clinical samples (*p* \> 0.05) (Table [4](#Tab4){ref-type="table"}).Table 4Association of methicillin resistant *S. aureus* to different clinical specimens at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, EthiopiaType of specimenMRSAMSSATotalCOR95 % CI*P*-valueN (%)N (%)N^a^Pus/abscess24(20.3)94(79.7)1180.511(0.11, 2.19)0.366Nasal swab3(33.3)6(66.7)90.638(0.11, 3.49)0.605Throat swab2(28.6)5(71.4)70.000-0.999Vaginal discharge0(0)3(100)30.000-0.999Urine0(0)6(100)61.915(0.41, 8.95)0.409Eye swab0(0)2(100)20.000-0.999Blood2(11.8)15(88.2)170.000-0.999Body fluids0(0)4(100)40.000-0.999Stool0(0)3(100)30.000-1.000Ear discharge3(12.5)21(87.5)241.787(0.49, 6.49)0.378Sputum0(0)1(100)11\--*COR* crude odds ratio^a^ total *S. aureus* isolates from each type of sample

Antimicrobial susceptibility pattern of *S. aureus* {#Sec15}
---------------------------------------------------

*S. aurues* isolated in this study were highly resistant to penicillin (187, 96.4 %), trimethoprim-sulphamethoxazole (103, 53.1 %), erythromycin (103, 53.1 %) and ciprofloxacin (61, 31.4 %). On the contrary, lower resistant was manifested by amoxicillin-clavulanate (36, 18.5 %), gentamicin (26, 13.4 %), clindamycin (23, 11.9 %) and vancomycin (10, 5.1 %) (Table [5](#Tab5){ref-type="table"}).Table 5Antimicrobial susceptibility pattern of *S. aureus* strains to different antimicrobial agents at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, EthiopiaAntibioticsResistantSusceptibleN (%)N (%)Cefoxitin \[30 μg\]34(17.5)160(82.5)Amoxicillin-clavulanate \[30 μg\]36(18.5)158(81.5)Penicillin G \[10 U\]187(96.4)7(3.6)Vancomycin^a^10(5.1)184(94.9)SXT \[1.25/23.75 μg\]103(53.1)91(46.9)Chloramphenicol \[30 μg\]36(18.6)158(81.4)Gentamycin \[10 μg\]26(13.4)168(86.6)Cefuroxime \[30 μg\]40(20.6)154(79.4)Clindamycin \[30 μg\]23(11.9)171(88.1)Ciprofloxacin \[5 μg\]61(31.4)133(68.6)Cephalothin \[10 μg\]37(19.1)157(80.9)Erythromycin \[15 μg\]103(53.1)91(46.9)*SXT* Trimethoprim-Sulfamethoxazole^a^ concentration from 2 μg/ml to16μg/ml

All isolates were resistant to at least one antimicrobial agent. MRSA isolates were 100 % resistant for penicillin, erythromycin, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate, cefuroxime, cephalothin and least resistant for vancomycin (10, 29.4 %). On the other hand, (153, 95.6 %) of MSSA were resistant to penicillin. Being resistant/susceptible for methicillin had a statistically significant chance of being resistant/susceptible for amoxicillin-clavulanate, cefuroxime and clindamycin (Table [6](#Tab6){ref-type="table"}).Table 6Association of methicillin resistant and sensitive *S. aureus* to different antimicrobial classes at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, EthiopiaAntibioticsMRSA (*n* = 34)MSSA (*n* = 160)AOR95 % CI*P*-valueN (%)N (%)AMC \[30 μg\]34(100)2(1.3)9.809(1.56, 61.69)0.015^\*^Penicillin G \[10 U\]34(100)153(95.6)0.000-0.99Vancomycin^a^10(29.4)0(0)0.000-0.99SXT \[1.25/23.75 μg\]34(100)69(43.1)16.24(0.41, 63.28)0.135Chloramphenicol \[30 μg\]16(47)20(12.5)1.130(0.09, 13.63)0.923Gentamycin \[10 μg\]13(38.2)13(8.1)0.896(0.07, 10.98)0.931Cefuroxime \[30 μg\]34(100)6(3.8)216.17(10.8, 432.2)0.001^\*\*^Clindamycin \[30 μg\]18(53)5(3.1)13.22(1.99, 87.62)0.007^\*\*^Ciprofloxacin \[5 μg\]28(82.5)33(20.6)0.615(0.10, 3.73)0.598Erythromycin \[15 μg\]34(100)69(43.1)9.044(0.49, 16.05)0.136Cephalothin \[10 μg\]34(100)3(1.8)1\--*AMC* Amoxilin- clavulanic acid, *SXT* Trimethoprim-Sulfamethoxazole^a^ concentration from 2 μg/ml to16μg/ml^\*\*^ Significant at *P* value \< 0.01, ^\*^ Significant at *P* value \< 0.05

Multi-drug resistance (MDR) and Beta-lactamase production pattern of *S. aureus* {#Sec16}
--------------------------------------------------------------------------------

Ninety-eight (50.5 %) of the isolates were multi-drug resistance. According to Magiorakos et al. \[[@CR15]\] MDR is defined as non-susceptibility to at least one agent in three or more antimicrobial categories. A higher number of multi-drug resistances were observed in triple drugs among penicillin G, erythromycin and trimethoprim-sulfamethoxazole (18, 18.4 %), and quadruple drugs among penicillin G, erythromycin, trimethoprim-sulphamethoxazole and ciprofloxacin (13, 13.26 %). Thirty (30.64 %) of multi-drug resistance was observed by triple drugs. Penicillin resistant was seen in all multi-drug resistant strains of *S. aureus* (Table [7](#Tab7){ref-type="table"}). Of 194 *S. aureus* isolates, (153, 79.0 %) were beta-lactamase producers. Furthermore, of 34 MRSA isolates (30, 88.2 %) and out of 160 MSSA strains (123, 76.8 %) were produced beta-lactamase.Table 7Multi*-*drug resistance nature of *S. aureus* isolates at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, EthiopiaAntibioticsResistant strainsN%P, E, SXT1818.40P, G, E55.10P, C, SXT44.08P, C, CIP33.06P, CIP, E, SXT1313.26P, G, C, E33.06P, G, C, SXT22.04P, CIP, E, SXT11.02P, AMC, E, SXT11.02P, FOX, G, SXT11.02P, FOX, E, SXT22.04P, C, CIP, E, SXT22.04P, G, CIP, AMC, SXT11.02P, G, CIP, E, SXT11.02P, G, C, E, SXT11.02P, CIP, E, SXT, DA22.04P, FOX, C, E, SXT11.02P, G, C, CIP, CXM, SXT11.02P, G, C, CIP, E, SXT33.06P, G, C, AMC, E, SXT11.02P, FOX, CIP, E, SXT, DA33.06P, FOX, C, E, CXM, SXT22.04P, G, C, CIP, E, SXT, DA22.04P, FOX, G, C, CIP, E, SXT22.04P, FOX, C, CIP, E, CXM, SXT55.10P, FOX, C, E, CXM, SXT, DA11.02P, FOX, CIP, AMC, KF, E, CXM22.04P, FOX, CIP, AMC, KF, SXT, DA22.04P, FOX, G, C, CIP, E, CXM, SXT22.04P, FOX, VAN, CIP,AMC, E, SXT, DA55.10P, FOX, VAN, CIP, AMC, E, CXM, SXT, DA11.02P, FOX, C, CIP, AMC, E, CXM, SXT, DA11.02P, FOX, VAN, CIP, AMC, KF, E, SXT, DA11.02P, FOX, VAN, G, C, CIP, AMC, E, SXT, DA11.02P, FOX, VAN, G, C, CIP, AMC, E, CXM, SXT, DA22.04Total98100.00*P* Penicillin G, *CIP* Ciprofloxacin, *AMC* Amoxicillin-clavulanic acid, *C* Chloramphenicol, *FOX* Cefoxitin, *KF* Cephalothin, *E* Erythromycin, *G* Gentamycin, *VAN* Vancomycin, *SXT* Trimethoprim-sulphamethoxazole, *DA* Clindamycin, *CXM* Cefuroxime

Discussion {#Sec17}
==========

The present study showed that males had a higher isolation rate of *S. aureus* than females. Rate of isolation of *S. aureus* was also the highest in 15--24 years of age group. Prevalence of MRSA in the present study, however, did not vary significantly by gender (*p* = 0.87) and age group (*p* \> 0.05) and this is in agreement with earlier reports by Geyid et al. \[[@CR16]\] indicating that gender and age are not risk factor for the acquisition or colonization of MRSA. The prevalence of MRSA was found to be 17.5 % which is less than that had been reported in Addis Ababa \[[@CR16], [@CR17]\] and outside Addis Ababa \[[@CR18]\]. Different studies have depicted variations in the prevalence rates of MRSA in different countries. Over 50 % prevalence rate of MRSA was reported in Portugal and Italy; 25 % in England, Greece and France; 2 % in the Netherlands and Switzerland \[[@CR19]\]. Prevalence of MRSA ranged from 23.6 % in Australia to over 61 % in Taiwan and Singapore, and more than 70 % in Japan and Hong Kong \[[@CR20]\]. Differences in the length of study period, number of study sites, sample size, sample type and the laboratory procedures employed may be factors that could contribute to variations in the prevalence rate of MRSA \[[@CR21]\]. The rate of MRSA obtained in this study however, was nearly the same as MRSA prevalence rate recorded in a pan-European data that was obtained from studies conducted among 43 laboratories from 10 European countries \[[@CR22]\].

Although no statistical association existed between isolation rates of MSRA and MSSA with any of clinical samples (*p* \>0.05), the present study depicted that prevalence of MRSA and MSSA isolated from pus was the highest as compared to other clinical samples. This finding is in agreement with the result obtained in Ethiopia \[[@CR16], [@CR18]\] and many similar studies \[[@CR21], [@CR23], [@CR24]\] conducted in other parts of the world. A highest isolation rate of *S. aureus* in general and MRSA in particular in pus in our study could partly be due to the fact that most of the wound samples came from surgical wards and burn unit of the hospital. MRSA on surgical wards is becoming increasingly common especially in critically ill patients who have spent prolonged periods on the intensive care units \[[@CR22], [@CR23]\].

Even though this study was not designed to identify risk factors for MRSA acquisition, risk factors that have previously been associated with acquisition of MRSA in hospitals such as broad-spectrum antimicrobial therapy, admission to an intensive care unit, older age and proximity to other patients with MRSA \[[@CR25]\] could play a major role in our study site. Antimicrobial susceptibility test on all the 194 *S. aureus* isolates against 12 commonly used antibiotics indicated that (187, 96.4 %) were resistant to penicillin and this finding was in agreement with the findings of Abera et al. \[[@CR18]\]. The lowest drug resistant was observed for vancomycin (10, 5.1 %). Furthermore, (98, 50.5 %) of the isolates were multi-drug resistant which is consistent with a study in Ethiopia at Bahir Dar \[[@CR18]\]. But it was less than the results reported at Addis Ababa \[[@CR16]\]. This variation could be explained in terms of periods of study, hygienic practice of the population, difference in socio-cultural and economic activity of the community.

All MRSA isolates encountered in this study were completely resistant (100 %) to antibiotics such as penicillin, erythromycin and trimethoprim-sulfamethoxazole. Similar results were noted for penicillin among MRSA strains in India \[[@CR26]\] and Trinidad & Tobago \[[@CR21]\]. Unlike most studies in Ethiopia \[[@CR16], [@CR17]\] and elsewhere in the world \[[@CR21], [@CR27]\] vancomycin resistance was very high. Ten (5.1 %) out of 194 *S. aureus* isolates were resistant to vancomycin and of 34 MRSA, (10, 29.4 %) were vancomycin resistant. A similar result was obtained for vancomycin resistance in previous reports in Trinidad \[[@CR28]\], and Argentina, Brazil, Chile, Mexico and Uruguay \[[@CR29]\]. MRSA strains which were also resistant to vancomycin in previous studies ranged from none (0 %) in Ethiopia, Karachi and Uganda \[[@CR16], [@CR27], [@CR30]\] to 8 % in Iran, Malaysia and Nigeria \[[@CR31]--[@CR33]\] which are lower than the current study. A study in United States and Latin American countries reported that most MRSA strains are resistant to other antibiotics, thereby necessitating the use of glycopeptides antibiotics, such as vancomycin. Treatment failure has been incriminated as a cause of decreased susceptibility of staphylococci to vancomycin \[[@CR34]\]. Wise use and continuous surveillance susceptibility testing of MRSA against vancomycin have been reported as a remedy to control reduced susceptibility of staphylococci to vancomycin \[[@CR35]--[@CR37]\].

In the present study all *S. aureus* isolates were tested for beta-lactamase production. It has been shown that out of 194 isolates (153, 79.0 %) were beta-lactames producers. Beta-lactamase producing strains of *S. aureus* in the present study were much higher than that has been reported by previous study conducted in Ethiopia \[[@CR16]\] but more or less the same as reported in India \[[@CR38]\] and Nigeria \[[@CR14]\]. Our study further depicted that out of 34 MRSA strains (30, 88.2 %) produced beta-lactamase and out of 160 MSSA strains (123, 76.8 %) were found out to be beta-lactamase producers.

Conclusion {#Sec18}
==========

The prevalence of *S. aureus* and MRSA varies appreciably based on type of clinical samples. Pus was the main source of *S. aureus* and MRSA in the hospital settings. The prevalence of MRSA stains obtained in this study was low when compared with the prevalence rates obtained in previous studies conducted in Ethiopia. However, the prevalence rate was considerably high when compared to other similar studies conducted elsewhere. MRSA strains were multidrug-resistant and unusually high numbers of isolates were resistant to vancomycin, the drug of choice for treating multidrug resistant MRSA infections. Reducing this burden by good infection control practices such as strict hand washing, identifying MRSA carriers and treating them as well as prudent use of antimicrobial agents is recommended. Further, genotypic studies are also needed to establish and characterize resistant strains of *S. aureus*.
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